(Q36709546)

English

The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?

scientific article published on February 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? (English)

1 reference

Europe PubMed Central

15 August 2017

metabolic syndrome

1 reference

based on heuristic

inferred from title

Dimitri P Mikhailidis

2

object named as

Dimitri P Mikhailidis

1 reference

Europe PubMed Central

15 August 2017

Evangelos N Liberopoulos

0 references

author name string

Asterios Karagiannis

1

1 reference

Europe PubMed Central

15 August 2017

Vasilios G Athyros

3

1 reference

Europe PubMed Central

15 August 2017

Anna I Kakafika

4

1 reference

Europe PubMed Central

15 August 2017

Konstantinos Tziomalos

5

1 reference

Europe PubMed Central

15 August 2017

Evangelos N Liberopoulos

6

1 reference

Europe PubMed Central

15 August 2017

Matilda Florentin

7

1 reference

Europe PubMed Central

15 August 2017

Moses Elisaf

8

1 reference

Europe PubMed Central

15 August 2017

language of work or name

0 references

publication date

1 February 2007

1 reference

Europe PubMed Central

15 August 2017

Expert Opinion on Therapeutic Targets

1 reference

Europe PubMed Central

15 August 2017

11

1 reference

Europe PubMed Central

15 August 2017

2

1 reference

Europe PubMed Central

15 August 2017

191-205

1 reference

Europe PubMed Central

15 August 2017

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Dyslipidaemia, hypercoagulability and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Prevention and treatment of the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Obesity, Metabolic Syndrome, and Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin signalling and the regulation of glucose and lipid metabolism

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Adverse endothelial function and the insulin resistance syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Role of insulin resistance in the genesis of sodium sensitivity in essential hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Serum-insulin in essential hypertension and in peripheral vascular disease

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin and blood pressure among healthy children. Cardiovascular risk in young Finns

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin causes endothelial dysfunction in humans: sites and mechanisms.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Epidemic Obesity and the Metabolic Syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Diagnosis and management of the metabolic syndrome in obesity

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Blood pressure and adiposity in children and adolescents.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Secular blood pressure trends in normotensive persons: the Framingham Study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Body weight, weight change, and risk for hypertension in women

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Is there a rationale for angiotensin blockade in the management of obesity hypertension?

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Mechanisms of hypertension and kidney disease in obesity

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why).

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Human adipocytes secrete mineralocorticoid-releasing factors

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Obesity-related hypertension: is there a role for selective leptin resistance?

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Splanchnic lipolysis in human obesity

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Weight change is associated with change in arterial stiffness among healthy young adults

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Cross-talk between the insulin and angiotensin signaling systems

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin blockade prevents type 2 diabetes by formation of fat cells

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Ramipril and the development of diabetes.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Adverse prognostic significance of new diabetes in treated hypertensive subjects

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Predictors of stroke mortality in elderly people from the general population. The CArdiovascular STudy in the ELderly

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Uric acid: role in cardiovascular disease and effects of losartan

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

A causal role for uric acid in fructose-induced metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Analysis of the relationship between fasting serum uric acid and the insulin sensitivity index in a population-based sample of 380 young healthy Caucasians.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Uric acid levels and vascular disease

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of losartan/diuretic combination treatment on serum uric acid levels in hypertensive patients.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Clinical profile of eprosartan

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Elevation of sympathetic activity by eprosartan in young male subjects

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

New treatment strategies for patients with hypertension and insulin resistance

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Safety of telmisartan in patients with arterial hypertension : an open-label observational study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Possible beneficial effect of telmisartan on glycemic control in diabetic subjects

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Effect of ramipril on the incidence of diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The ONTARGET/TRANSCEND Trial Programme: baseline data

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

The DREAM trial – Authors' reply

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.2.191

21 January 2018

Identifiers

10.1517/14728222.11.2.191

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36709546&oldid=1516413125"